FDA Grants Priority Review for Takeda’s Narcolepsy Drug Oveporexton
Event summary
- FDA accepted Takeda’s New Drug Application (NDA) for Oveporexton (TAK-861) as a potential first-in-class therapy for narcolepsy type 1 (NT1).
- Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency in NT1.
- FDA set a Prescription Drug User Fee Act (PDUFA) goal date in Q3 2026 for a decision.
- Phase 3 studies (FirstLight and RadiantLight) showed statistically significant improvements in wakefulness, excessive daytime sleepiness, cataplexy, and quality of life.
The big picture
Takeda’s Oveporexton represents a potential first-in-class therapy for narcolepsy type 1, addressing a significant unmet need in rare neurological diseases. The FDA’s Priority Review designation underscores the drug’s innovative mechanism and clinical promise. Success could solidify Takeda’s leadership in orexin science, with broader implications for its pipeline of related therapies.
What we're watching
- Regulatory Timeline
- Whether the FDA will meet its PDUFA goal date in Q3 2026 for Oveporexton’s approval.
- Market Differentiation
- How Oveporexton’s orexin receptor 2 selectivity positions it against existing narcolepsy treatments.
- Pipeline Expansion
- The pace at which Takeda advances its broader orexin franchise, including TAK-360 for narcolepsy type 2 and idiopathic hypersomnia.
Our editorial coverage:
Related topics